( CARLSBAD Calif. March 22 2007 /PRNe...)Isis Pharmaceuticals Announces Its Participation at the Upcoming,ACC 56th Annual Scientific Session in New Orleans and Its Live,Analyst/Investor Webcast Presentation,Health

CARLSBAD, Calif., March 22, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals announces that results from three Phase 2 studies of ISIS 301012, including effects of ISIS 301012 in homozygous familial hypercholesterolemic (HoFH) patients, will be the subjects of three upcoming presentations at the of Cardiology (ACC), March 24-27 in New Orleans. Planned presentations include effects of ISIS 301012 in patients both as monotherapy and added to stable statin therapy. An overall summary of the Phase 2 program results for ISIS 301012 will be provided at the March 27 Analyst/Investor webcast presentation, along with a summary of Isis' development plan for ISIS 301012. ISIS 301012 is the Company's cholesterol-lowering drug targeting apoB-100.

    Sunday, March 25, 2007


    Session:          1206:  Vascular Disease, Hypertension and Prevention --

                      V-cast Poster


    Track:            ACC.Vascular Disease, Hypertension, and Prevention


    Room:             Hall H


    Presentation:     1206-278


    Abstract:         Statin-Like, Dose-Dependent Reductions in LDL-C and

                      Apolipoprotein B With ISIS 301012, an Antisense

                      Inhibitor of Apolipoprotein B, in Subjects With

                      Polygenic Hypercholesterolemia


    Monday, March 26, 2007


    Session:          603:  Common Challenges in Preventive Cardiology

                      (7:00 - 8:30 a.m. CT)


    Track:            ACC.Symposium


    Room:             Auditorium B


    Presentation:     603-8


    Time:             8:15 - 8:30 a.m.


    Speaker:          Dr. Evan A. Stein


    Title:            High Low-Density Lipoprotein Cholesterol on Three Drugs*

                      *to include preliminary results of an ongoing study

                      evaluating ISIS 301012 in HoFH patients on concurrent

                      maximally tolerated lipid-lowering therapies


    Session:          820:  Clinical Trials of 
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4
Inhibitor, ARI-2243, at the ADA